Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

A newly approved pain medication, suzetrigine, is the first nonopioid analgesic in 25 years to receive clearance from the U.S ...

A federal judge on Tuesday ordered U.S. health agencies to restore websites that they abruptly took offline in response to an executive order by President Donald Trump telling them to scrub websites ...

Stocks reversed early Friday gains, extending lows in stages after mixed employment and inflation expectations data. Late morning headlines regarding "reciprocal tariff" implementation as early as ...

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and more.

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 10 unusual trades. Delving into ...

Vertex Pharmaceuticals, which makes the drug, has billed it as an effective alternative to opioids that isn’t addictive. Journavx works by intercepting pain signals before they reach the spinal ...